Altamira Therapeutics Ltd. - רווח למניה לשנה מתגלגלת CYTO

Altamira Therapeutics (CYTO) currently generates revenue through the sale of anti-allergen sprays and the implementation of RNA technologies. The company is expanding its internal potential via M&A transactions and the integration of the Peptide+ platform into partner projects. However, liquidity shortages and litigation are creating pressure, as evidenced by this GURU.Markets chart: the daily price action of the rolling annual EPS YoY indicates that the value of the metric is 5.50.
CYTO (altamiratherapeutics.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This metric is calculated as the percentage deviation of current net earnings per share from the same value for the previous year. The metric measures the dynamics of the business's real earnings, allowing for an assessment of capital management efficiency. For Altamira Therapeutics (CYTO), this growth is driven by the low demand elasticity for the SemaPoly platform. Strong pricing power in the RNA delivery segment converts directly into profit. By analyzing the history of year-over-year EPS changes (TTM), an investor can determine the sustainability of this business model.